Comparative Pharmacology
Head-to-head clinical analysis: INDERIDE LA 160 50 versus INDERIDE 80 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDERIDE LA 160 50 versus INDERIDE 80 25.
INDERIDE LA 160/50 vs INDERIDE-80/25
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Propranolol: Non-selective beta-adrenergic receptor antagonist (blocks β1 and β2 receptors). Hydrochlorothiazide: Thiazide diuretic inhibiting Na+/Cl- cotransporter in distal convoluted tubule, reducing intravascular volume by increasing sodium and water excretion.
INDERIDE-80/25 is a combination of propranolol (a non-selective beta-adrenergic receptor antagonist) and hydrochlorothiazide (a thiazide diuretic). Propranolol blocks beta-1 and beta-2 adrenergic receptors, reducing heart rate, myocardial contractility, and renin release, thereby lowering blood pressure. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the kidney, increasing excretion of sodium, chloride, and water, reducing plasma volume.
HypertensionAngina pectoris (propranolol)Migraine prophylaxis (propranolol)Essential tremor (propranolol)Edematous states (hydrochlorothiazide)
Management of hypertension (FDA-approved)Off-label: prevention of migraine, essential tremor, angina pectoris
One capsule orally once daily. Each capsule contains propranolol hydrochloride 160 mg and hydrochlorothiazide 50 mg. Dosage should be individualized; typical maintenance dose is 1 capsule per day.
One tablet (80 mg propranolol/25 mg hydrochlorothiazide) orally twice daily.
None Documented
None Documented
Propranolol: 3-6 hours (parent drug), 8-12 hours (4-hydroxypropranolol active metabolite) with prolonged half-life in hepatic impairment; Hydrochlorothiazide: 6-15 hours, extended in renal impairment (creatinine clearance <30 mL/min).
Propranolol: 3-6 hours (single dose), prolonged with chronic dosing (up to 12 hours). Hydrochlorothiazide: 6-15 hours; prolonged in renal impairment.
Propranolol: Hepatic via CYP2D6 and glucuronidation; active metabolite 4-hydroxypropranolol. Hydrochlorothiazide: Not extensively metabolized, excreted unchanged in urine.
Propranolol is extensively metabolized in the liver via cytochrome P450 enzymes, primarily CYP2D6 and CYP1A2, forming active metabolites (e.g., 4-hydroxypropranolol). Hydrochlorothiazide is not metabolized and is excreted unchanged in urine.
Propranolol: primarily hepatic metabolism to inactive metabolites, <1% excreted unchanged in urine; Hydrochlorothiazide: 50-70% excreted unchanged in urine, remainder as metabolites via renal and biliary routes.
Renal: 40% unchanged propranolol; 60% as metabolites. Biliary/fecal: minimal (less than 1%). Hydrochlorothiazide: renal 95% unchanged.
Propranolol: 90-95% bound to albumin; Hydrochlorothiazide: 40-68% bound to albumin.
Propranolol: 90-95% bound to albumin; hydrochlorothiazide: 68% bound to albumin.
Propranolol: 3-5 L/kg, indicating extensive tissue penetration; Hydrochlorothiazide: 0.83-1.14 L/kg, consistent with distribution into extracellular fluid.
Propranolol: 4 L/kg (large Vd due to lipophilicity); hydrochlorothiazide: 0.8 L/kg (restricted to extracellular fluid).
Propranolol: 25-30% due to extensive first-pass hepatic metabolism; Hydrochlorothiazide: 65-75% after oral administration.
Propranolol: 30% (oral) due to extensive first-pass metabolism; bioavailability increased with food or chronic dosing. Hydrochlorothiazide: 65-70% (oral).
For GFR <30 mL/min: contraindicated due to thiazide component. For GFR 30-60 mL/min: reduce dose or increase interval based on clinical response; monitor electrolytes and renal function.
GFR 30-60 mL/min: reduce dose or extend interval; GFR <30 mL/min: contraindicated due to hydrochlorothiazide component.
In Child-Pugh A: reduce propranolol dose by 50%. Child-Pugh B or C: avoid use or use with extreme caution; propranolol undergoes extensive hepatic metabolism.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Safety and efficacy not established; not recommended for use in pediatric patients.
Not recommended for children; safety and efficacy not established.
Initiate at lower dose (e.g., one-half capsule) due to increased sensitivity and age-related renal/hepatic decline; titrate slowly. Monitor orthostatic hypotension, bradycardia, and electrolyte disturbances.
Initiate at lowest dose; monitor renal function and orthostatic hypotension; adjust based on response and tolerability.
No black box warning is listed for INDERIDE LA 160/50 in standard FDA labeling. Propranolol may exacerbate angina and precipitate myocardial infarction with abrupt discontinuation; taper dose gradually.
Exacerbation of angina pectoris and myocardial infarction upon abrupt discontinuation of beta-blockade; taper dose gradually.
Heart failure, bronchospasm (asthma/COPD), bradycardia, hypotension, peripheral vascular disease, thyrotoxicosis (may mask signs), myocardial ischemia (abrupt withdrawal), diabetes (mask hypoglycemia), electrolyte imbalance (especially hypokalemia from thiazide), hyperuricemia, systemic lupus erythematosus exacerbation.
May exacerbate heart failure, bronchospasm, and mask hypoglycemia in diabetic patients. Use caution in patients with renal impairment (monitor electrolytes and renal function). Hydrochlorothiazide can cause electrolyte imbalances, hyperglycemia, and hyperuricemia.
Cardiogenic shock, sinus bradycardia, second- or third-degree AV block, sick sinus syndrome (without pacemaker), overt heart failure, bronchial asthma, hypersensitivity to beta-blockers or thiazides, anuria, severe renal impairment (creatinine clearance <30 mL/min).
Bronchial asthma, sinus bradycardia, heart block (greater than first degree), cardiogenic shock, decompensated heart failure, anuria (for hydrochlorothiazide component), hypersensitivity to any component.
Data Pending Review
Data Pending Review
Avoid high-potassium foods (e.g., bananas, oranges, spinach, salt substitutes) in excess, as hydrochlorothiazide affects potassium balance. Limit alcohol consumption. Maintain a low-sodium diet to reduce fluid retention and enhance antihypertensive effect. Avoid grapefruit products as they may alter drug metabolism.
Avoid high-sodium foods to prevent blunting of antihypertensive effect. Limit potassium-rich foods (bananas, oranges) due to hyperkalemia risk from HCTZ. Grapefruit juice may increase propranolol levels. Alcohol may potentiate hypotension.
Propranolol (component of Inderide LA 160/50) crosses the placenta and is associated with intrauterine growth restriction, neonatal hypoglycemia, bradycardia, and respiratory depression, especially with third-trimester exposure. First-trimester use may increase risk of spontaneous abortion. Risk cannot be excluded; use only if benefit outweighs risk.
INDERIDE-80/25 contains propranolol (a beta-blocker) and hydrochlorothiazide (a thiazide diuretic). Propranolol: First trimester: limited human data, no clear increased risk of major malformations, but possible fetal bradycardia and growth restriction; Second and third trimesters: risk of intrauterine growth restriction, neonatal hypoglycemia, bradycardia, and respiratory depression at delivery. Hydrochlorothiazide: First trimester: based on limited data, no major teratogenic risk; Second and third trimesters: may cause fetal or neonatal jaundice, thrombocytopenia, electrolyte disturbances, and potential placental hypoperfusion.
Both propranolol and hydrochlorothiazide are excreted into breast milk. Propranolol M/P ratio: 0.5-1.5. Hydrochlorothiazide may suppress lactation. American Academy of Pediatrics considers propranolol compatible but caution with hydrochlorothiazide. Monitor infant for bradycardia, hypotension, and electrolyte disturbances.
Propranolol is excreted into breast milk in small amounts; the M/P ratio is approximately 0.3-0.5. Infant dose is less than 1% of maternal weight-adjusted dose, considered compatible with breastfeeding. Hydrochlorothiazide is also excreted into breast milk, but levels are low; M/P ratio unknown. However, thiazides may suppress lactation and cause neonatal electrolyte disturbances. Use with caution, especially in newborns with impaired renal function.
Pregnancy may increase clearance of propranolol, potentially requiring higher doses to maintain efficacy. Dose adjustment should be guided by clinical response and maternal heart rate. Avoid use of hydrochlorothiazide in pregnancy due to risk of fetal/neonatal adverse effects; consider alternative antihypertensive.
Propranolol: Pregnancy may increase clearance, potentially requiring dose increase; however, beta-blockers generally require careful titration to avoid fetal bradycardia. Hydrochlorothiazide: Pregnancy may decrease efficacy due to increased volume of distribution; avoid in preeclampsia due to potential placental hypoperfusion. In general, use the lowest effective dose, monitor maternal response, and consider pregnancy-induced pharmacokinetic changes.
Category C
Category C
INDERIDE LA 160/50 combines propranolol HCl (160 mg) and hydrochlorothiazide (50 mg). Monitor heart rate and blood pressure regularly; propranolol can mask hypoglycemia symptoms in diabetics and thyrotoxicosis. Hydrochlorothiazide may cause electrolyte disturbances; check potassium, magnesium, and sodium. Avoid abrupt withdrawal due to risk of angina exacerbation or MI. Use with caution in patients with asthma, COPD, bradycardia, or heart block.
Combination product of propranolol (80 mg) and hydrochlorothiazide (25 mg). Propranolol is a non-selective beta-blocker; contraindicated in asthma, bradycardia, and heart block. Monitor for bronchospasm, hypoglycemia (masks symptoms), and bradycardia. Hydrochlorothiazide (HCTZ) is a thiazide diuretic; check electrolytes, renal function, and for gout/hyperuricemia. Titrate doses separately before switching to combination. Avoid abrupt withdrawal of beta-blocker (risk of myocardial ischemia).
Take this medication exactly as prescribed, usually once daily in the morning.Do not stop taking this medication suddenly without consulting your doctor, as this may worsen chest pain or increase risk of heart attack.This drug may cause dizziness or lightheadedness; avoid driving if affected and rise slowly from sitting or lying position.Monitor your blood pressure regularly and keep a log to share with your healthcare provider.If you have diabetes, check your blood sugar more often; propranolol can hide signs of low blood sugar like rapid heartbeat.Avoid alcohol as it may increase side effects like dizziness or drowsiness.Report any unusual weight gain, swelling, excessive thirst, dry mouth, or muscle cramps to your doctor.Do not take other medications for blood pressure or heart conditions without doctor approval.Limit caffeine intake as it may increase heart rate and counteract the effects.
Take exactly as prescribed, usually once daily in the morning to avoid nocturia.Do not stop abruptly; consult doctor before discontinuing (risk of chest pain or heart attack).May cause dizziness or lightheadedness; avoid driving if affected.Report slow heartbeat, fainting, difficulty breathing, or swelling.Monitor for increased blood sugar if diabetic; beta-blockers may hide signs of low blood sugar.Avoid excessive sweating or dehydration; stay well-hydrated.Limit alcohol and caffeine intake as they may affect blood pressure.Use sunscreen; medication may increase sensitivity to sunlight.